Format

Send to

Choose Destination
Heart. 2018 Dec;104(23):1910-1919. doi: 10.1136/heartjnl-2018-313397. Epub 2018 Aug 18.

Chronic heart failure management and remote haemodynamic monitoring.

Author information

1
Division of Cardiovascular Medicine, University of Southern California, Los Angeles, California, USA.

Abstract

Heart failure (HF) has a large societal and economic burden and is expected to increase in magnitude and complexity over the ensuing years. A number of telemonitoring strategies exploring remote monitoring and management of clinical signs and symptoms of congestion in HF have had equivocal results. Early studies of remote haemodynamic monitoring showed promise, but issues with device integrity and implantation-associated adverse events hindered progress. Nonetheless, these early studies established that haemodynamic congestion precedes clinical congestion by several weeks and that remote monitoring of intracardiac pressures may be a viable and practical management strategy. Recently, the safety and efficacy of remote pulmonary artery pressure-guided HF management was established in a prospective, single-blind trial where randomisation to active pressure-guided HF management reduced future HF hospitalisations. Subsequent commercial use studies reinforced the utility of this technology and post hoc analyses suggest that tight haemodynamic management of patients with HF may be an additional pillar of therapy alongside established guideline-directed medical and device therapy. Currently, there is active exploration into utilisation of this technology and management paradigm for the timing of implantation of durable left ventricular assist devices (LVAD) and even optimisation of LVAD therapy. Several ongoing clinical trials will help clarify the extent and utility of this strategy along the spectrum of patient with HF from individuals with chronic, stable HF to those with more advanced disease requiring heart replacement therapy.

KEYWORDS:

heart failure

Conflict of interest statement

Competing interests: DMS, LG, JR and AMW are on the speakers' bureau for Abbott Vascular, the manufacturer of the CardioMEMS HF System. DMS, LG, JR and MF receive research support from Abbott Vascular.

Publication type

Publication type

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center